Assembly Biosciences, Inc. (ASMB) Stock Forecast
ASMB analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $52.00 average of analyst targets
- Upside to target
- +158.8% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.44
- 52-week range
- $20.09 – $38.50
ASMB analyst ratings
5 analystsNumber of analysts at each rating.
ASMB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ASMB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.49 | −$1.12 | −$0.16 | −$0.72 | +31.3% | 4 |
| Current fiscal year (2026) | −$0.12 | −$2.86 | $2.28 | −$0.55 | +78.6% | 4 |
| Next fiscal year (2027) | −$2.57 | −$4.83 | $0.05 | −$0.12 | −2,086.0% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ASMB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $7.3M | $0 | $12.5M | −32.7% | 5 |
| Current fiscal year (2026) | $63.4M | $22.0M | $112.9M | −12.3% | 5 |
| Next fiscal year (2027) | $34.1M | $0 | $74.1M | −46.2% | 5 |
ASMB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ASMB revenue: reported and forecast
ASMB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.51 | −$0.51 | −$0.51 | −$0.49 | −$0.49 | −2.0% | 2 up · 0 down |
| Current fiscal year (2026) | $0.14 | $0.14 | $0.14 | −$0.12 | −$0.12 | −184.1% | 2 up · 0 down |
| Next fiscal year (2027) | −$2.71 | −$2.10 | −$2.10 | −$2.59 | −$2.57 | −5.0% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ASMB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ASMB beat in 10 of 12.
What analysts expect from ASMB
5 analysts cover Assembly Biosciences; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $52.00, 158.8% above the latest close of $20.09. Analysts expect earnings of −$0.12 per share for 2026, +78.6% from a year earlier. For 2027 the average estimate is −$2.57 per share on revenue of $34.1 million. Assembly Biosciences beat the EPS estimate in 10 of the last 12 quarters.
Related: ASMB income statement, ASMB key metrics, ASMB chart. See the ASMB stock overview for the latest quote and news.
ASMB forecast FAQ
What is Assembly Biosciences's price target?
The average analyst price target for Assembly Biosciences is $52.00, 158.8% above the latest close of $20.09.
Is Assembly Biosciences a buy, hold or sell?
Of 5 analysts covering Assembly Biosciences, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Assembly Biosciences's EPS forecast?
Analysts forecast −$0.12 per share for 2026 (range −$2.86 to $2.28); for 2027 the estimate is −$2.57.
What is Assembly Biosciences's revenue forecast?
The average revenue estimate for 2026 is $63.4 million, growth of −12.3%; for 2027 it is $34.1 million.
When does Assembly Biosciences report earnings?
Assembly Biosciences is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-0.44.
Does Assembly Biosciences usually beat earnings estimates?
Assembly Biosciences reported EPS at or above the analyst estimate in 10 of the last 12 quarters.